Suppr超能文献

侵袭性肺曲霉病与接受静脉-静脉体外膜肺氧合治疗的危重症患者的不良临床结局相关。

Invasive pulmonary aspergillosis is associated with adverse clinical outcomes in critically ill patients receiving veno-venous extracorporeal membrane oxygenation.

机构信息

Infectious Diseases Department, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

Microbiology Department, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

出版信息

Eur J Clin Microbiol Infect Dis. 2018 Jul;37(7):1251-1257. doi: 10.1007/s10096-018-3241-7. Epub 2018 Apr 6.

Abstract

To identify the incidence, risk factors and impact on long-term survival of invasive pulmonary aspergillosis (IPA) and Aspergillus colonisation in patients receiving vv-extracorporeal membrane oxygenation (ECMO). A retrospective evaluation was performed of patients receiving vv-ECMO at a tertiary hospital in Manchester (UK) between January 2012 and December 2016. Data collected included epidemiological data, microbiological cultures, radiographic findings and outcomes. Cases were classified as proven IPA, putative IPA or Aspergillus colonisation according to a validated clinical algorithm. One hundred thirty-four patients were supported with vv-ECMO, median age of 45.5 years (range 16.4-73.4). Ten (7%) patients had putative IPA and nine (7%) had Aspergillus colonisation. Half of the patients with putative IPA lacked classical host risk factors for IPA. The median number of days on ECMO prior to Aspergillus isolation was 5 days. Immunosuppression and influenza A infection were significantly associated with developing IPA in a logistic regression model. Cox regression model demonstrates a three times greater hazard of death associated with IPA. Overall 6-month mortality rate was 38%. Patients with putative IPA and colonised patients had a 6-month mortality rate of 80 and 11%, respectively. Immunosuppression and influenza A infection are independent risk factors for IPA. IPA, but not Aspergillus colonisation, is associated with high long-term mortality in patients supported with vv-ECMO.

摘要

目的

明确体外膜肺氧合(ECMO)支持患者侵袭性肺曲霉病(IPA)和曲霉菌定植的发病率、危险因素和对长期生存的影响。方法:回顾性分析 2012 年 1 月至 2016 年 12 月期间在英国曼彻斯特一家三级医院接受 vv-ECMO 治疗的患者的临床资料。收集的资料包括流行病学数据、微生物培养、影像学发现和结局。根据经过验证的临床算法,将病例分为确诊 IPA、疑似 IPA 和曲霉菌定植。结果:共 134 例患者接受 vv-ECMO 治疗,中位年龄为 45.5 岁(16.4-73.4 岁)。10 例(7%)患者疑似 IPA,9 例(7%)患者曲霉菌定植。疑似 IPA 患者中有一半缺乏 IPA 的经典宿主危险因素。在 ECMO 前分离出曲霉菌的中位时间为 5 天。Logistic 回归模型显示,免疫抑制和甲型流感感染与 IPA 的发生显著相关。Cox 回归模型显示,IPA 患者的死亡风险增加了 3 倍。总体 6 个月死亡率为 38%。疑似 IPA 和定植患者的 6 个月死亡率分别为 80%和 11%。免疫抑制和甲型流感感染是 IPA 的独立危险因素。IPA 而非曲霉菌定植与 vv-ECMO 支持患者的长期高死亡率相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a155/7101780/448fddc0c4cc/10096_2018_3241_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验